While inhibiting the receptor with the simultaneous administration of anti-CD47 monoclonal antibodies, the phagocytosis and killing capacity of macrophages on tumor cells is significantly increased (46) (Figure 3B). The gene discussed is CD47; the disease is neoplasm.